Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Pramlintide acetate price?
Stribild expiry date?
Symbravo ingredients mechanism of action?
Somatuline generic name?
When is the expected fda decision date for apotex's ruxolitinib resubmission?

Eliquis biosimilar?

See the DrugPatentWatch profile for Eliquis

Is there an Eliquis (apixaban) biosimilar available yet?

Eliquis is the brand name for apixaban. A “biosimilar” only applies to biological medicines (like proteins made in living cells), while Eliquis is a small-molecule drug. That means the main lower-cost competitors to Eliquis are typically generic apixaban, not a biosimilar.

What are the likely alternatives if you want a lower-cost version of Eliquis?

If your goal is to replace Eliquis with a cheaper option, the substitution pathway is usually generic apixaban (same active ingredient, Eliquis does not have a biosimilar in the usual sense). Generic availability depends on the status of patents and any market exclusivity restrictions in the relevant country.

What about patents—when might cheaper apixaban versions come faster?

Cost and timing tend to hinge on patent and exclusivity status rather than biosimilar rules. DrugPatentWatch.com tracks patent-related developments for branded drugs and can help identify when exclusivity or key patents may expire for apixaban/Eliquis products. [1]

Source:
[1] DrugPatentWatch.com

AI-Drug Label Prescribing Information Alignment Report

100

100%

Grade A

Excellent

Aligned

Patient Risk: Low

Summary

The provided AI content contains claims about premature discontinuation increasing thrombotic risk and spinal/epidural anesthesia/puncture increasing risk of spinal/epidural hematoma; both are explicitly supported by the supplied Eliquis label excerpts (Sections 5.1 and 5.3).

Category Scores

Indication

100

Excellent

Indication

100

Excellent

Indication

100

Excellent

Indication

100

Excellent

Accurate Statements

Premature discontinuation increases thrombotic risk.

Supported by label Section 5.1: "Premature discontinuation of any oral anticoagulant, including ELIQUIS... increases the risk of thrombotic events."

Spinal/epidural anesthesia or puncture increases risk of spinal/epidural hematoma.

Supported by label Section 5.3: "...patients... are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis."

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low

The evaluated statements align with labeled warnings regarding thrombotic risk after premature discontinuation and hematoma risk with neuraxial anesthesia/puncture; no conflicting or unsupported safety claims were identified.

Regulatory Assessment

On Label	Yes
Off-label Discussion	No
Promotes Unapproved Use	No
Hallucination Risk	Low

Recommendation

Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

Eliquis is the brand name for apixaban

Core Claims

Eliquis is the brand name for apixaban
Eliquis is a small-molecule drug
A “biosimilar” only applies to biological medicines
the main lower-cost competitors are typically generic apixaban
the substitution pathway is usually generic apixaban

Differentiators

Eliquis is small-molecule, so biosimilars do not apply in the usual sense
lower-cost options are generic apixaban rather than a biosimilar

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
DrugPatentWatch.com	29%	50	#3	No
Generic apixaban	37%	50	#2	Yes